What BMI for Mounjaro: UK Thresholds, NICE Guidance and Exceptions

What BMI for Mounjaro is required in the UK? Mounjaro (tirzepatide) is licensed for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above when at least one weight-related health condition is present. Understanding these thresholds, how NICE guidance applies, and what happens if your BMI falls just below the cut-off is essential before approaching any service. This article explains the licensed criteria, the role of comorbidities, NHS versus private access, and how to check whether you may qualify.

What BMI do you need to be prescribed Mounjaro in the UK?

Mounjaro requires a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related health condition, for the chronic weight-management indication; no BMI threshold applies to the type 2 diabetes indication.

For chronic weight management, Mounjaro (tirzepatide) is indicated in the UK for adults with a BMI of 30 kg/m² or above, or a BMI of 27 kg/m² or above when at least one weight-related health condition is also present. These thresholds are set out in the UK Summary of Product Characteristics (SmPC) for Mounjaro, available on the Electronic Medicines Compendium (EMC). They apply specifically to the chronic weight-management indication. For the type 2 diabetes indication, no BMI threshold is specified in the licence; prescribing decisions for diabetes are based on glycaemic control and clinical need rather than BMI.

The SmPC also states that tirzepatide should be used alongside a reduced-calorie diet and increased physical activity.^[1][8] It is not a standalone treatment, and a prescriber will expect patients to engage with dietary and lifestyle changes as part of their weight-management plan.

Mounjaro is authorised by the MHRA both for type 2 diabetes management and for chronic weight management, so the indication a prescriber is working within determines which criteria apply.^[1][8]

A prescriber will not rely on BMI alone. A full clinical assessment typically considers your weight history, current medications, relevant comorbidities, and whether lifestyle interventions have already been tried. BMI is a useful screening tool but has recognised limitations, particularly for people from South Asian, Black African or Black Caribbean backgrounds, where health risks associated with excess weight can occur at lower BMI values. Some clinicians and services therefore apply ethnicity-adjusted thresholds, informed by UK public health guidance.

Bolt Pharmacy is a GPhC-registered online pharmacy in Great Britain offering weight-management consultations, where a prescriber may consider Mounjaro as one possible option following a thorough clinical review, and only where it is clinically appropriate. Accessing any weight-management medicine should always begin with an honest and complete health assessment, not with a BMI figure alone.

Does your BMI threshold change if you have a weight-related condition?

Yes, having at least one qualifying weight-related condition, such as type 2 diabetes, hypertension, or obstructive sleep apnoea, lowers the Mounjaro BMI threshold from 30 kg/m² to 27 kg/m².

Yes, having at least one weight-related health condition lowers the qualifying BMI threshold for Mounjaro from 30 kg/m² to 27 kg/m². This lower threshold recognises that excess weight causes clinically significant harm at a wider range of body weights when other conditions are present, and that earlier intervention may reduce the burden of those conditions.

The UK SmPC and NICE guidance on tirzepatide for weight management identify weight-related conditions that are relevant in this context. These include:

• Type 2 diabetes

• Hypertension (high blood pressure)

• Dyslipidaemia (abnormal blood lipid levels)

• Obstructive sleep apnoea

• Cardiovascular disease

Other conditions associated with excess weight, such as non-alcoholic fatty liver disease or certain musculoskeletal conditions, may also be considered by a prescriber, but their inclusion depends on clinical judgement and the specific service's criteria rather than being explicitly named in the SmPC. If you have a condition not on the list above, discuss it with your prescriber, who can advise whether it is relevant to your assessment.

The presence of a qualifying condition must be confirmed clinically, not simply self-reported. A prescriber will typically review relevant medical records, recent blood results, or a GP letter to verify the diagnosis before applying the lower threshold. This is an important safeguard, because prescribing at a lower BMI without a genuine comorbidity would fall outside the licensed indication.

Having a qualifying comorbidity does not guarantee that Mounjaro is the most appropriate treatment. A prescriber will weigh up the full clinical picture, including any contraindications, current medications that might interact, and whether the individual is already receiving treatment for the comorbidity in question. Patients should be prepared to discuss their full medical history openly during any consultation.

How NICE and NHS guidelines set the BMI cut-offs for Mounjaro

NICE appraises tirzepatide for NHS use through a technology appraisal, and its criteria may be narrower than the MHRA licence; NHS organisations in England must fund NICE-recommended treatments within three months of final guidance.

NICE has appraised tirzepatide (Mounjaro) for chronic weight management in adults through a technology appraisal process.^[2][6] The NICE recommendation sets criteria for NHS use that may be narrower than the full licensed indication, reflecting cost-effectiveness considerations and the need to prioritise those with the greatest clinical need within available resources. Patients and clinicians should check the current NICE guidance directly on the NICE website for the most up-to-date criteria, including any BMI subgroups, service-setting requirements, or duration limits that apply to NHS use.

It is important to understand the distinction between what NICE recommends for NHS use and what the MHRA has authorised. The MHRA authorises a medicine for use in the UK based on its safety and efficacy profile. NICE then assesses cost-effectiveness and recommends whether the NHS should fund it, and for which patient groups. In England, NHS organisations have a statutory duty to fund and make available treatments recommended by NICE technology appraisals, normally within three months of final guidance being published.^[13] Regional variation in access therefore tends to reflect differences in service pathway, capacity, and implementation rather than discretionary decisions about whether to fund the treatment at all.

Equivalent decisions in Scotland are made by the Scottish Medicines Consortium (SMC), in Wales by the All Wales Medicines Strategy Group (AWMSG), and in Northern Ireland by the Department of Health. Patients in those nations should check the relevant body's website for the current position, as decisions may differ from those in England.

For patients accessing Mounjaro privately, the relevant threshold is the licensed indication rather than the NICE recommendation, provided a prescriber is satisfied that the clinical criteria are met. Prescribers working outside NHS specialist services are still bound by the terms of the licence and by their professional obligations to their regulatory body.

What if your BMI is just below the threshold, are there any exceptions?

There is no automatic exception for a BMI below the standard threshold; however, ethnicity-adjusted thresholds (2.5 kg/m² lower) may be applied for certain ethnic groups at higher cardiometabolic risk, at the prescriber's clinical discretion.

If your BMI falls below the standard thresholds, there is no automatic exception that would make Mounjaro appropriate, and a responsible prescriber should not prescribe it outside the licensed indication without clear clinical justification. Prescribing outside a licence is legally permissible in the UK in certain circumstances, but it carries additional professional responsibility and requires explicit documentation of the clinical rationale, in line with GMC guidance on good practice in prescribing and managing medicines. It is not a routine pathway for weight management.

One area where clinical judgement may lead to a lower threshold being applied is ethnicity. NICE and NHS guidance acknowledge that people from South Asian, Chinese, Black African and Black Caribbean backgrounds face increased cardiometabolic risk at lower BMI values. Some services apply a BMI threshold that is 2.5 kg/m² lower for these groups, meaning a threshold of 27.5 kg/m² (or 25 kg/m² with a comorbidity) may be considered appropriate. This is a service-level policy informed by UK public health guidance rather than a requirement of the SmPC, and its application depends on the clinical service and the prescriber's judgement.

If your BMI is close to but below the standard threshold, the most appropriate step is to speak with your GP. They can assess whether your overall clinical picture, including any comorbidities, ethnicity-related risk factors, or previous weight management attempts, supports a referral to a specialist service or a discussion about alternative options. Attempting to access weight-management medicines through services that do not apply proper clinical thresholds carries real safety risks, and a BMI figure alone is never sufficient grounds for prescribing.

How do you check whether your BMI qualifies before approaching a service?

Use the NHS BMI calculator at nhs.uk for an accurate starting point, and gather your weight, height, diagnosed conditions, current medications, and recent blood results before approaching any regulated weight-management service.

You can calculate your BMI before approaching any service using the NHS BMI calculator, available at nhs.uk/live-well/healthy-weight/bmi-calculator, which also provides guidance on what your result means for your health. BMI is calculated by dividing your weight in kilograms by the square of your height in metres.^[7] As a starting point, a result of 30 or above, or 27 or above with a weight-related health condition, indicates you may meet the licensed criteria for Mounjaro for weight management.

When checking your BMI, use accurate, recent measurements rather than estimates. Weigh yourself without shoes or heavy clothing, and measure your height carefully. Small inaccuracies can place you either side of a threshold, so precision matters. If you are unsure, your GP surgery can measure both accurately.

Before approaching any online or private weight-management service, it is worth gathering the following information:

• Your current weight and height (to confirm your BMI)

• A list of any diagnosed health conditions, particularly those listed as weight-related comorbidities

• Your current medications, including over-the-counter and herbal products

• Any relevant recent blood test results, such as HbA1c, blood pressure readings or lipid panels

When evaluating a provider, check that they are registered with the relevant regulator. In Great Britain, online pharmacies must be registered with the General Pharmaceutical Council (GPhC), which maintains a public register at pharmacyregulation.org; in Northern Ireland, with the Pharmaceutical Society of Northern Ireland (PSNI) at psni.org.uk. Healthcare services in England should be registered with the Care Quality Commission (CQC) at cqc.org.uk; in Scotland with Healthcare Improvement Scotland at healthcareimprovementscotland.org; in Wales with Healthcare Inspectorate Wales at hiw.org.uk; and in Northern Ireland with the Regulation and Quality Improvement Authority (RQIA) at rqia.org.uk. You can verify prescribers on the General Medical Council register at gmc-uk.org. A legitimate service will always conduct a clinical assessment before any prescribing decision is made.

Frequently Asked Questions